Ratios Reveal: Breaking Down ProKidney Corp (PROK)’s Financial Health

Nora Barnes

The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.

ProKidney Corp (NASDAQ: PROK) closed the day trading at $2.5 up 1.63% from the previous closing price of $2.46. In other words, the price has increased by $1.63 from its previous closing price. On the day, 0.95 million shares were traded. PROK stock price reached its highest trading level at $2.5699 during the session, while it also had its lowest trading level at $2.41.

Upgrades & Downgrades

In the most recent recommendation for this company, H.C. Wainwright on December 16, 2025, initiated with a Buy rating and assigned the stock a target price of $12. On June 30, 2025, BofA Securities Downgraded its rating to Underperform which previously was Neutral but kept the price unchanged to $1.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 13 ’25 when Pereira Brian JG sold 502,136 shares for $2.37 per share. The transaction valued at 1,190,062 led to the insider holds 0 shares of the business.

Pereira Brian JG sold 255,026 shares of PROK for $694,515 on Nov 12 ’25. The Director now owns 54,333 shares after completing the transaction at $2.72 per share. On Nov 12 ’25, another insider, Brian Pereira, who serves as the Director of the company, bought 675,234 shares for $2.70 each.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PROK now has a Market Capitalization of 752085888 and an Enterprise Value of 1412732672. For the stock, the TTM Price-to-Sale (P/S) ratio is 1016.33. Its current Enterprise Value per Revenue stands at 1898.834 whereas that against EBITDA is -8.584.

Stock Price History:

The Beta on a monthly basis for PROK is 1.82, which has changed by 0.36666667 over the last 52 weeks, in comparison to a change of 0.13927746 over the same period for the S&P500. Over the past 52 weeks, PROK has reached a high of $7.13, while it has fallen to a 52-week low of $0.46. The 50-Day Moving Average of the stock is -3.85%, while the 200-Day Moving Average is calculated to be 28.28%.

Shares Statistics:

Over the past 3-months, PROK traded about 1.67M shares per day on average, while over the past 10 days, PROK traded about 1481510 shares per day. A total of 135.98M shares are outstanding, with a floating share count of 105.52M. Insiders hold about 25.45% of the company’s shares, while institutions hold 28.52% stake in the company. Shares short for PROK as of 1764288000 were 14786117 with a Short Ratio of 8.83, compared to 1761868800 on 12294628. Therefore, it implies a Short% of Shares Outstanding of 14786117 and a Short% of Float of 14.37.

Earnings Estimates

Its stock is currently analyzed by 6.0 different market analysts. The consensus estimate for the next quarter is -$0.16, with high estimates of -$0.16 and low estimates of -$0.16.

Analysts are recommending an EPS of between -$0.41 and -$1.07 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.64, with 6.0 analysts recommending between -$0.42 and -$1.2.

Revenue Estimates

5 analysts predict -$39.4k in revenue for. The current quarter. It ranges from a high estimate of $250k to a low estimate of -$447k. As of. The current estimate, ProKidney Corp’s year-ago sales were $76k

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.